in the frequency or severity of adverse events, including infection, between the treatment arms.
Conclusion. In patients with GCA, the addition of abatacept to a treatment regimen with prednisone reduced the risk of relapse and was not associated with a higher rate of toxicity compared to prednisone alone.
Giant cell arteritis (GCA) is a chronic granulomatous vasculitic disease of unknown cause that preferentially involves medium-and large-sized arteries, such as the carotid arteries, aorta, and their major branches (1) (2) (3) . GCA typically affects individuals older than age 50 years and is the most common systemic vasculitis seen in the Northern Hemisphere (4) . Glucocorticoids have been recognized as an effective treatment for GCA, resulting in improvement in symptoms and prevention of cranial ischemic complications, including blindness (5, 6) . However, glucocorticoids are associated with significant toxicity, particularly in the older patient population affected by this disease (7) . This morbidity risk is further compounded by the occurrence of disease relapse in at least 70% of patients, thereby necessitating long-term therapy with glucocorticoids (8) . It has therefore been a high priority and unmet need in GCA to identify safer, effective therapeutic options beyond glucocorticoids.
Although the cause of GCA remains unknown, experimental data suggest that GCA is an antigen-driven disease in which activated T lymphocytes, macrophages, and dendritic cells play a critical role in the disease pathogenesis (9) (10) (11) (12) . Abatacept is composed of the ligandbinding domain of CTLA-4 as well as a modified Fc domain derived from IgG1. CTLA-4 binds to CD80 and CD86 with a higher avidity than that to CD28, thereby acting as a negative regulator of CD28-mediated T cell costimulation. With CTLA-4 as a component, abatacept blocks the engagement of CD28 with its ligand, thereby inhibiting T cell activation (13) (14) (15) . Abatacept is approved by the US Food and Drug Administration for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, in which it has been found to have a low rate of toxicity, with the main side effects being hypersensitivity and infection, most commonly including upper respiratory tract infections, bronchitis, and herpes zoster.
Based on the rationale that blockage of T cell activation might impact disease pathogenesis in GCA, together with the favorable toxicity profile that has been seen with abatacept (16) (17) (18) , a randomized trial was conducted with the objectives of investigating the efficacy and safety of abatacept in the treatment of GCA.
PATIENTS AND METHODS
Design overview. The protocol for this randomized trial was written by 2 of the authors (CAL and PAM) in collaboration with the Steering Committee of the Vasculitis Clinical Research Consortium and the Rare Diseases Clinical Research Network Data Management and Coordinating Center (DMCC) (additional protocol information can be found at https://www.rarediseasesnetwork.org/cms/VCRC). The original study protocol and all amendments were approved by an independent Data and Safety Monitoring Board and by the Institutional Review Board at each site. There were no significant changes made to the study methods after trial commencement. Research was carried out in compliance with the Declaration of Helsinski, and all patients provided written informed consent.
Setting and participants. The trial was conducted at 11 academic medical centers (additional study site participants within the Vasculitis Clinical Research Consortium are listed in Appendix A). Enrolled patients were individuals with newly diagnosed or relapsing GCA who had active disease within the prior 2 months. All patients met the American College of Rheumatology modified classification criteria for GCA (19) , in which they were required to have 3 of the following 5 criteria, with 1 of the 3 required criteria consisting of either the fourth or the fifth criterion: 1) age at disease onset .50 years; 2) new onset or new type of localized pain in the head; 3) erythrocyte sedimentation rate (ESR) .40 mm in the first hour by the Westergren method; 4) a temporal artery abnormality (i.e., temporal artery tenderness to palpation or decreased pulsation, unrelated to arteriosclerosis of the cervical arteries); and 5) temporal artery or large vessel biopsy showing vasculitis, characterized by a predominance of mononuclear cell infiltration or granulomatous inflammation, usually with multinucleated giant cells or characteristic changes of large vessel stenosis or aneurysm by arteriography. Exclusion criteria included active infection (including chronic infection, infection with the human immunodeficiency virus, hepatitis C virus, hepatitis B virus, or tuberculosis), pregnancy, breastfeeding, cytopenias, recent live vaccination, history of any malignant neoplasm except basal or squamous cell carcinoma of the skin or solid tumors adequately treated with curative therapy and with absence of disease for at least 5 years, comorbidities that would increase the risk of study participation or that required treatment with glucocorticoids, and prior therapy with a biologic agent given within established time parameters.
Interventions. All eligible patients were treated with abatacept (Bristol-Myers Squibb) at a dose of 10 mg/kg (500 mg for ,60 kg body weight, 750 mg for 60-100 kg, and 1,000 mg for .100 kg) by intravenous infusion on days 1, 15, and 29 and week 8, together with prednisone at a dosage of 40-60 mg/day followed by a standardized tapering schedule (for more details, see Supplementary Table 1 , available on thetreatment of GCA or to restart prednisone after discontinuation was considered a relapse criterion.
In the absence of meeting criteria for early termination, abatacept or placebo was continued until a common closing date, which was 12 months after enrollment of the final patient. Potential reasons for early termination included the following: failure to experience remission by the week 12 visit, disease relapse, pregnancy or breastfeeding, development of malignancy with the exception of basal or squamous cell carcinoma of the skin that had been completely excised, grade 4 toxicity, hypersensitivity reactions to abatacept, noncompliance with study procedures, or discontinuation of treatment when, in the medical judgment of the physician, it was deemed in the best interests of the patient. Patients who experienced a relapse discontinued their study drug and were treated according to best medical judgment. Following discontinuation of their study drug, patients were asked to return for posttreatment visits at weeks 4, 12, and 24, after which time they were considered off study.
Randomization and blinding. Randomization was computer-generated by the DMCC in a 1:1 allocation that was balanced by clinical site, utilizing randomly permuted blocks. Patients and all study investigators were blinded with regard to the randomized treatment assignment.
Assessment and follow-up of outcomes. The assessment used to determine disease activity was obtained in a standardized manner throughout the study. A clinical history, physician examination, and laboratory tests were obtained at each study visit. All patients without contraindications underwent magnetic resonance imaging of the aorta and branches at study entry. In patients found to have involvement of the large vessels, this imaging was repeated at 6-month intervals and at the time of early termination/common close.
The primary end point was duration of remission (relapse-free survival rate). Remission was defined as the absence of disease activity, and relapse was based on the presence of disease activity. The determination of disease activity was defined according to preestablished clinical and imaging criteria, when these features were not attributable to other causes. Clinical criteria included the following features: a sustained fever of .388C for more than 1 week, vascular pain/tenderness producing symptoms such as carotidynia, scalp tenderness, or temporal artery abnormalities that were present for .1 day and nonfleeting, headache that was present for .1 day, nonfleeting, not fully relieved with nonnarcotic analgesics, and not typical for any preexisting form of headaches experienced by the patient, ischemic retinopathy, optic neuropathy, visual loss, tongue/jaw pain and/or claudication, transient cerebral ischemia, stroke, extremity claudication, or symptoms/signs attributed to GCA by the investigator that necessitated reinstitution or an increased dosage of glucocorticoids. Musculoskeletal symptoms or fatigue/malaise could be considered to be features of active disease if they occurred in combination with an ESR of .40 mm in the first hour by the Westergren method or a C-reactive protein (CRP) measurement above the laboratory normal limit. An elevation in acutephase reactant levels was not considered indicative of disease activity in the absence of clinically compatible disease manifestations. Imaging features of active disease were the development of new vascular stenosis or aneurysm in new vascular territories, as seen by magnetic resonance, computed tomography, or conventional dye arteriography. Determination of relapse was assessed by both the site investigator and study principal investigator during the blinded phase, and reaffirmed by the study team following the end of the trial. No changes were made to the outcome definitions during the course of the trial.
The secondary end point was toxicity. All adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (details available at . Randomization assignment at week 12. All patients were initially treated with abatacept and prednisone. At week 12, those in remission underwent a blinded randomization at a 1:1 ratio to receive placebo or to continue to receive abatacept. All randomized patients were included in the intent-to-treat analysis.
ABATACEPT FOR THE TREATMENT OF GCA 839 http://ctep.cancer.gov). Study visits and data collection occurred at screening, at baseline, at each infusion of study drug, at early termination/common close, and at the posttreatment visits. Statistical analysis and sample size determination. The 12-month relapse-free survival rate in patients with GCA treated with prednisone was estimated to be 30%, based on prior values reported in the literature (8) . The planned sample size for the trial of 30 randomized patients was based on an 80% probability of detecting a clinically meaningful difference between the treatment arms, set as a 30% improvement in the relapse-free survival rate and utilizing a one-sided alpha value of 0.1.
Kaplan-Meier curves of relapse-free survival were constructed, and differences in treatment arms were compared using the log rank test. The analysis of the primary outcome was based on intent-to-treat. The secondary study end point was toxicity. Adverse events were recorded throughout the trial and analyzed after randomization, with tabulation by treatment arm. The frequency of occurrence of each event was compared between the treatment groups by Fisher's exact test.
Safety monitoring and guidelines for stopping treatment. Conduct of the study was overseen by an independent Data and Safety Monitoring Board and the Institutional Review Board at each study site. Rules for halting new patient accrual were established prior to trial initiation and consisted of any deaths that were possibly, probably, or definitely related to the study drug or any grade 4 toxicities that were probably or definitely related to the study drug.
RESULTS
Patient population. There were 58 patients with GCA who provided their written informed consent and underwent protocol screening between February 2009 and January 2014 (a time point at which the study enrollment goals were met) (Figure 2 ). Nine of the 58 patients were not eligible. Thus, 49 patients received the study drug. Eight of these 49 patients were withdrawn from the study, experienced a relapse, or were not in remission at week 12, resulting in a randomized study population of 41 patients. The baseline clinical and demographic features of the 41 randomized patients are listed in Table 1 . Thirty-two patients had undergone a temporal artery biopsy, with the results being positive in 25 patients.
Twenty patients were randomized to receive abatacept and 21 to receive placebo. Thirty-four of the 41 patients met the end point of relapse or follow-up in remission at week 64. The 7 patients who either voluntarily withdrew or who were withdrawn by the investigator prior to week 64 were included in the analysis, using their status at the last available follow-up. Of the 41 randomized patients, 7 voluntarily withdrew or were withdrawn by the investigator prior to week 64. These were included in the intent-to-treat analysis, using their status at the last available follow-up. Of these 7 patients, 3 were randomized to receive abatacept; of the 3 patients, 1 voluntarily withdrew after experiencing a relapse at 8 weeks after the last infusion, 1 was withdrawn by the site investigator because of severe infection and experienced a relapse 6 weeks after the last infusion, and 1 was withdrawn by the site investigator and was in remission at last follow-up. Of the 4 patients randomized to receive placebo, 3 voluntarily withdrew and all were in remission at last follow-up, and 1 patient was withdrawn because of malignancy and was also in remission at last follow-up.
Efficacy assessments. In the intent-to-treat analysis of the 41 randomized patients, the relapse-free survival rate at 12 months was 48% for those receiving abatacept and 31% for those receiving placebo (P 5 0.049) (Figure 3) . A longer median duration of remission was seen in patients treated with abatacept (median duration 9.9 months) compared to those receiving placebo (median duration 3.9 months; P 5 0.023). 
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A covariate analysis examining those variables that were statistically significantly different between the study treatment arms demonstrated that sex, age at diagnosis, and age at enrollment did not impact the study results.
The relapses that were observed during the trial reflected typical characteristics of GCA (Table 2) . Only 1 patient experienced a cranial ischemic complication at relapse during the randomized treatment period, with partial vision loss assumed to be secondary to GCA that resolved with reinstitution of glucocorticoids. Another patient experienced a branch retinal artery occlusion attributed to active GCA, but this occurred during the posttreatment follow-up period 5 months after stopping abatacept and while being managed according to best medical judgment. An elevation in the ESR and/or CRP levels above the normal range was seen in the majority of patients who experienced relapse.
Of the 17 patients who remained in remission (10 receiving abatacept and 7 receiving placebo), 3 declined to return for posttreatment visits. The other 14 patients all remained in remission during the extended follow-up period, of whom 4 were in remission through posttreatment week 12 and 10 were in remission through posttreatment week 24 (see Supplementary Table 2 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40044/abstract). For those who reached the common close date while in remission, the total duration of study treatment ranged from 64 weeks to 304 weeks.
A prespecified subset analysis was performed on the population of 34 patients who relapsed or were in remission at week 64, in which the difference between treatment arms became larger. The relapse-free survival rate at 12 months in this subset of patients was 52.9% for those receiving abatacept and 23.5% for those receiving placebo (P 5 0.014).
Adverse events. Overall, 129 adverse events occurred in 35 patients, including 23 serious adverse events in 15 patients. There was no difference in the frequency or severity of adverse events between the treatment arms, including the rate of infection or the rate of serious adverse events (Table 3) . No deaths occurred during the study.
A total of 33 infections were reported during the trial in 20 patients. Twenty-nine infections occurred in the randomized population, with 4 occurring in patients who did not undergo randomization. There was no statistically significant difference in the frequency of infections between the 2 treatment arms. Two infections required hospitalization and were reported as serious adverse events. Among the randomized patients, 6 infections in 4 patients occurred within the first 12 weeks. All 4 infections that occurred in the nonrandomized patients developed after discontinuation of abatacept, with 2 occurring within 3 months of the last drug administration and 2 occurring more than 3 months after the last administration.
Of the 49 treated patients, 3 developed malignancies during the study period. These malignancies included a papillary urothelial transitional cell carcinoma in 1 patient randomized to receive abatacept who received the last dose of study drug at week 76, an endometrial carcinoma in 1 patient randomized to receive abatacept who received the last dose of study drug at week 96, and a skin squamous cell carcinoma treated with radiation therapy in a patient randomized to receive placebo.
DISCUSSION
Since the 1950s, glucocorticoids have represented the foundation of treatment for GCA. Although effective, glucocorticoids are associated with substantial toxicity, and relapse of vasculitis occurs in a high percentage of patients. Identifying other effective treatment options that may lessen the risk of relapse in GCA has been the goal of a number of previous well-designed studies (8, (20) (21) (22) (23) (24) . Although methotrexate has arguably shown the greatest benefit, it has, at most, a modest effect in GCA (8, 20, 23, 24) . Abatacept represents an attractive agent to investigate in the treatment of patients with GCA because of the drug's favorable safety profile and because of the mechanism of action modulating T cell activation that was hypothesized to play a role in the pathophysiology of GCA.
In this randomized withdrawal-design trial, patients who achieved remission and were randomized to continue to receive abatacept had a significantly higher rate of relapse-free survival compared to those who were randomized to receive placebo, providing supportive evidence of the efficacy of abatacept in this study population. This difference between groups is clinically meaningful in patients with GCA, corresponding to a prolonged duration of remission, during which time they are not exposed to glucocorticoids and the potential toxicity of glucocorticoids that may impact quality of life. These findings are particularly impactful given the older patient population affected by this disease, which is the most common form of primary systemic vasculitis.
In seeking to identify a less toxic treatment option in GCA, the safety of abatacept was an important aspect of this study. High-dose prednisone is associated with significant side effects, and one concern was whether the addition of abatacept would increase the risk of infection or other side effects. The results of the comparative analysis between study arms indicated no difference in the type or severity of adverse events seen between those randomized to receive abatacept and those who received placebo. There was also no signal suggestive of enhanced toxicity during the first 12 weeks, when all patients concurrently received combined treatment with high-dose glucocorticoids and abatacept.
Since a standardized prednisone taper was applied to both treatment arms and since all patients had reached a prednisone dosage of 20 mg/day at the time of randomization and had discontinued prednisone at week 28, there was by definition no difference in prednisone dosage or duration between the study arms. This schedule was similar to those previously utilized in clinical trials of GCA, and it allowed sufficient time before the primary end point analysis to assess the impact of the study drug without prednisone.
A number of factors strengthen these results. This trial was conducted by clinician investigators experienced in the care of patients with GCA and clinical trials, which provided an enhanced ability to evaluate parameters of disease activity as well as monitor for toxicity in these older patients. The choice of a doubleblind, randomized, withdrawal design was attractive for several reasons. Because there had been no prior experience with abatacept in GCA or the use of abatacept combined with high-dose prednisone, this design, in which all patients initially received abatacept with highdose prednisone, provided an ideal opportunity to gain initial efficacy data and to assess safety that would be relevant to clinical practice.
This study has some limitations to consider. One of the greatest investigational and clinical challenges in GCA is that there remains no definitive indicator for disease activity, and assessment of remission and relapse is based on clinical and imaging parameters. The definitions of disease activity used in this trial were prespecified within the protocol and required a higher burden of evidence for those features that were the most subjective. Moreover, the definitions that were used were based on those that are applied by practicing physicians and utilized parameters commonly assessed in the routine care of patients. Review of the disease characteristics of all relapses were adjudicated by both the site investigator and study principal investigator during the blinded phase and by the study team following the end of the trial, with no changes in outcome assessment being made after unblinding. The features of active disease at the time of relapses were convincing in both treatment arms, and provide strong support for the method of assessment of remission/active disease used in this study.
Despite the small sample size, the difference in relapse-free survival rates between treatment arms was statistically and clinically significant. In addition, a benefit associated with abatacept exceeding the clinically meaningful difference predefined in the study design was found in a secondary analysis of patients who experienced relapse or those who were in remission at 64 weeks, further strengthening these findings.
Although the small sample size could also potentially impact the role of confounding variables within the study, the influence of individual GCA characteristics on treatment response remains unclear. The study was not powered to demonstrate differences between specific features, such that any findings from the analysis of individual variables could be inaccurate and misleading. The planned design to look for a large difference between study arms that was felt to be clinically meaningful diminishes the impact that any unknown confounding variables could have had on the study findings.
This study also provides useful insights into the currently available measures of disease activity in GCA. ESR and CRP levels are commonly used biomarkers in GCA, but a rise in these markers did not accompany every relapse, including in the setting of otherwisecompelling features of disease activity, an observation previously noted (25) . These observations reflect the need for ongoing investigation of clinical, laboratory, and imaging biomarkers as well as patient-reported outcomes to better assess disease activity in GCA (26, 27) .
Although reduction in relapse would hopefully result in a reduction of overall medication-related morbidity, this trial does not allow conclusions to be drawn as to whether abatacept reduces the risk of glucocorticoidrelated toxicity in GCA. It is also important to recognize that abatacept was used as an adjunctive treatment with standard prednisone in this trial, and no conclusions should be reached regarding the effect of abatacept for the treatment of active GCA independent of glucocorticoids.
The ongoing development of novel agents that target specific immunologic components will continue to provide exciting opportunities for novel therapies in GCA. Tocilizumab, an interleukin-6 receptor blocker, has also been proposed as an adjunctive treatment for GCA (28, 29) , including in a phase III trial currently underway (30) . Every agent possesses a unique sideeffect profile that may make it contraindicated for certain patients. Continuing to investigate promising therapeutic options in GCA remains vitally important.
In conclusion, this study demonstrated that treatment of GCA with abatacept combined with glucocorticoids results in a longer duration of relapse-free survival than does treatment with prednisone alone, and is well tolerated. In the older patient population impacted by GCA, this potential for a glucocorticoid-sparing option is clinically important and meaningful.
